Revolution Medicines' cancer drug success

The success of the Phase 3 trial represents a potential breakthrough for one of the most difficult-to-treat forms of cancer.

Pancreatic cancer currently has a five-year survival rate below 20%, making new therapeutic options a critical priority for oncologists.

Revolution's experimental pill is designed to target specific genetic mutations that drive tumor growth.

Following the announcement, several analysts upgraded the stock, citing the drug's strong safety profile and its potential to become a standard-of-market treatment.